Trial tests new strategy to prevent Flare-Ups of devastating autoimmune disease
NCT ID NCT00748644
Summary
This study tested whether the drug rituximab is better than the standard drug azathioprine at keeping two severe autoimmune diseases (Wegener's granulomatosis and microscopic polyangiitis) in remission. It involved 117 adults whose disease was under control after initial treatment. Patients received either rituximab infusions every six months or daily azathioprine pills for 18 months to see which group had fewer major disease flare-ups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROSCOPIC POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Cochin
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.